Companies › Johnson & Johnson (Janssen)
66 active drug programs in 569 registered trials: 270 Phase 2, 149 Phase 1, 110 Phase 3, 40 Phase 4; Oncology, Immunology, Neurology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Guselkumab (CNTO1959) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease … | Dec 2026 |
| Ciltacabtagene Autoleucel (JNJ-68284528) Tumor necrosis factor receptor superfamily member 17 binding agent | TNFRSF17 | Phase 4 | Multiple Myeloma; Recurrent Multiple Myeloma; High Risk Smoldering Multiple Myeloma; Relapse Multiple Myeloma … | Feb 2027 |
| Daratumumab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 3 | Multiple Myeloma; Amyloidosis; Hemophilia A With Inhibitor; Microvascular Inflammation - MVI in Kindey Transplant Recipients … | Nov 2026 |
| Apalutamide Androgen Receptor antagonist | AR | Phase 3 | Prostatic Neoplasms; Metastatic Castrate-sensitive Prostate Cancer | Dec 2026 |
| Milvexian Coagulation factor XI inhibitor | F11 | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient; Atrial Fibrillation | Dec 2026 |
| Nipocalimab IgG receptor FcRn large subunit p51 antagonist | FCGRT | Phase 3 | Hemolytic Disease of the Fetus and Newborn; Myasthenia Gravis; Thrombocytopenia, Neonatal Alloimmune; Sjogrens Syndrome … | Dec 2026 |
| Cetrelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Urinary Bladder Neoplasms; Bladder Cancer; Prostatic Neoplasms, Castration-Resistant; Neoplasms … | Dec 2026 |
| Seltorexant Orexin receptor 2 antagonist | HCRTR2 | Phase 3 | Depressive Disorder, Major | Dec 2026 |
| Amivantamab Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor | EGFR, MET | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck … | Dec 2026 |
| Erdafitinib (TAR-210) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 3 | Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| Ibrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type … | Dec 2026 |
| Lazertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-small-Cell Lung; Non-Small-Cell Lung Cancer … | Dec 2026 |
| Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Prostatic Neoplasms; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms, Castration-Resistant; Ovarian Cancer … | Dec 2026 |
| selexipag Prostanoid IP receptor agonist | PTGIR | Phase 3 | Hypertension, Pulmonary; Pulmonary Arterial Hypertension | Dec 2026 |
| Pasritamig FGFR3 inhibitor | FGFR3 | Phase 3 | Prostatic Neoplasms, Castration-Resistant; Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms; Metastatic Castration-resistant Prostate Neoplasms | Jan 2027 |
| Macitentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 3 | Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary Hypertension | Jan 2027 |
| Golimumab TNF-alpha inhibitor | TNF | Phase 3 | Colitis, Ulcerative; Rheumatoid Arthritis; Peripheral Spondyloarthritis | Feb 2027 |
| Icotrokinra (JNJ-77242113) IL-6 receptor antagonist | IL6R | Phase 3 | Arthritis, Psoriatic; Plaque Psoriasis; Colitis, Ulcerative; Crohn Disease | Feb 2027 |
| Talquetamab T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent | CD3E, CD3G, CD3D, GPRC5D | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Teclistamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| JNJ-79635322 Bispecific antibody targeting CD3 and BCMA | CD3E, TNFRSF17 | Phase 3 | Multiple Myeloma; Relapsed or Refractory Multiple Myeloma | Apr 2027 |
| HLD-0915 (JNJ-101556143) HLD-0915; mechanism unclear from registry | – | Phase 3 | Prostatic Neoplasms; Metastatic Prostate Cancer | Jun 2027 |
| JNJ-87189401 PSMA-targeted CD28 co-stimulatory agonist bispecific antibody | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms | Jun 2027 |
| Bleximenib Menin inhibitor | MEN1 | Phase 3 | Leukemia, Myeloid, Acute; Acute Leukemia; Acute Myeloid Leukemia | Jun 2027 |
| Ustekinumab Interleukin-12 inhibitor; Interleukin-23 inhibitor | IL12B, IL12A, IL23A | Phase 3 | Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus … | Sep 2027 |
| JNJ-77242113 TYK2 inhibitor | – | Phase 3 | Generalized Pustular Psoriasis | Oct 2027 |
| Abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 3 | Prostatic Neoplasms; Prostate Cancer; Castration-Resistant Prostatic Cancer; Metastatic Prostate Cancer … | Nov 2027 |
| Ramantamig BCMAxGPRC5DxCD3 trispecific antibody | TNFRSF17, CD3E, BCMA, GPRC5D | Phase 3 | Multiple Myeloma | Dec 2027 |
| JNJ-78934804 IL-23 inhibitor | IL23A | Phase 3 | Crohn Disease; Colitis, Ulcerative; Crohn's Disease | Jun 2028 |
| JNJ-90301900 (NBTXR3) Hafnium oxide nanoparticles that generate oxygen free radicals when activated by ionizing | – | Phase 3 | Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck | Jun 2028 |
| Esketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Sleep Wake Disorders; Prenatal Depression … | Dec 2028 |
| JNJ-95597528 | – | Phase 2 | Dermatitis, Atopic; Asthma | Nov 2026 |
| JNJ-64042056 Anti-tau monoclonal antibody | – | Phase 2 | Alzheimer Disease | Dec 2026 |
| JNJ-88545223 | – | Phase 2 | Arthritis, Psoriatic | Jun 2027 |
| JNJ-81201887 AAV5-delivered CD59 complement regulator | CD59 | Phase 2 | Geographic Atrophy | Aug 2029 |
| JNJ-69086420 Actinium-225-labeled anti-hK2 antibody (alpha-particle emitting radiopharmaceutical) | KLK2 | Phase 1 | Prostatic Neoplasms | Dec 2026 |
| JNJ-78278343 KLK2-CD3 bispecific antibody (pasritamig) | KLK2, CD3E | Phase 1 | Prostatic Neoplasms | Dec 2026 |
| JNJ-89862175 | – | Phase 1 | Advanced-stage Solid Tumors | Dec 2026 |
| ARX517 anti-PSMA antibody-drug conjugate with microtubule-disrupting toxins | FOLH1 | Phase 1 | Metastatic Prostate Cancer | Dec 2026 |
| JNJ-90009530 autologous chimeric antigen receptor (CAR)-T cell therapy targeting CD20 | – | Phase 1 | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Jan 2027 |
| JNJ-86974680 ARv7 inhibitor | AR | Phase 1 | Prostatic Neoplasms | Jan 2027 |
| JNJ-87890387 | – | Phase 1 | Neoplasms | Mar 2027 |
| JNJ-75348780 CD3 T-cell engager | – | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| JNJ-80948543 T-cell redirecting trispecific antibody against CD79b, CD20, and CD3 | CD79B, CD20, CD3 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| Cetrelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Carcinoma, Non-small-Cell Lung; Neoplasms | Apr 2027 |
| JNJ-86974680 | – | Phase 1 | Carcinoma, Non-small-Cell Lung | Apr 2027 |
| Capmatinib Hepatocyte growth factor receptor inhibitor | MET | Phase 1 | Carcinoma, Non-Small-Cell Lung | Apr 2027 |
| JNJ-88549968 CALR-targeting therapy for calreticulin-mutated myeloproliferative neoplasms | CALR | Phase 1 | Neoplasms | Jun 2027 |
| Aticaprant (JNJ-67953964) Kappa opioid receptor antagonist | OPRK1 | Phase 1 | Schizophrenia | Jun 2027 |
| JNJ-90189892 | – | Phase 1 | Leukemia, Myeloid, Acute | Aug 2027 |
| JNJ-88998377 | – | Phase 1 | Lymphoma, Non-Hodgkin | Oct 2027 |
| JNJ-87562761 | – | Phase 1 | Relapsed or Refractory Multiple Myeloma | Nov 2027 |
| JNJ-95437446 | – | Phase 1 | Advanced Stage Solid Tumors | Nov 2027 |
| JNJ-95298177 | – | Phase 1 | Prostatic Neoplasms | Nov 2027 |
| PD-1 Inhibitor PD-1 inhibitor (specific agent not named) | – | Phase 1 | Relapsed/ Refractory Multiple Myeloma; Esophageal Squamous Cell Carcinoma; Esophageal Carcinoma; Advanced NSCLC … | Dec 2027 |
| JNJ-1761981 | – | Phase 1 | Neoplasms | Jan 2028 |
| JNJ-89402638 | – | Phase 1 | Colorectal Neoplasms | Feb 2028 |
| JNJ-101684362 (HLD-0117) | – | Phase 1 | Metastatic Breast Cancer | Apr 2028 |
| JNJ-87801493 | – | Phase 1 | Lymphoma, Non-Hodgkin | Aug 2028 |
| JNJ-95566692 | – | Phase 1 | Lymphoma, Non-Hodgkin | Aug 2028 |
| JNJ-87704916 Intratumoral immunotherapy agent | – | Phase 1 | Neoplasms | Nov 2028 |
| Olomorasib KRAS G12C inhibitor | KRAS | Phase 1 | Carcinoma, Non-Small-Cell Lung | Nov 2028 |
| JNJ-98768111 | – | Phase 1 | Prostatic Neoplasms | Mar 2029 |
| JNJ-95804306 | – | Phase 1 | Hematologic Neoplasms | May 2029 |
| JNJ-90014496 Autologous dual targeting CAR-T cell therapy targeting CD20 and CD19 | – | Phase 1 | Lymphoma, Non-Hodgkin | Jul 2041 |
| JNJ-89853413 | – | Phase 1 | Leukemia, Myeloid, Acute | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01589302 | Ibrutinib | Phase 2 | Prolymphocytic Leukemia | Oncology | Jul 2016 |
| NCT02048813 | Ibrutinib | Phase 3 | Anemia | Oncology | Oct 2018 |
| NCT03236428 | Daratumumab | Phase 2 | Monoclonal Gammopathy | Oncology | Oct 2021 |
| NCT04667663 | Daratumumab | Phase 1 | Multiple Myeloma | Oncology | Apr 2022 |
| NCT03734198 | Daratumumab | Phase 2 | Relapsed or Refractory Chronic Lymphocytic Leukemia | Oncology | Jun 2023 |
| NCT03734198 | Ibrutinib | Phase 2 | Relapsed or Refractory Chronic Lymphocytic Leukemia | Oncology | Jun 2023 |
| NCT04140162 | Daratumumab | Phase 2 | Multiple Myeloma | Oncology | May 2024 |
| NCT05601973 | Amivantamab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Aug 2024 |
| NCT05601973 | Lazertinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Aug 2024 |
| NCT04586426 | Teclistamab | Phase 1 | Multiple Myeloma | Oncology | Mar 2025 |
| NCT04586426 | Talquetamab | Phase 1 | Multiple Myeloma | Oncology | Mar 2025 |
| NCT02807805 | Abiraterone acetate | Phase 2 | Metastatic Prostate Carcinoma | Oncology | May 2025 |
| NCT03290950 | Daratumumab | Phase 2 | Multiple Myeloma | Oncology | May 2025 |
| NCT06920576 | Esketamine | Phase 1 | Chronic Rhinosinusitis | Respiratory | Jul 2025 |
| NCT05379634 | Nipocalimab | Phase 2 | Myositis | Other | Sep 2025 |
| NCT06778811 | Esketamine | Phase 4 | Sleep Wake Disorders | Neurology | Sep 2025 |
| NCT05870761 | Niraparib | Phase 2 | Recurrent Endometrial Serous Adenocarcinoma | Oncology | Sep 2025 |
| NCT05698394 | Esketamine | Phase 4 | Prenatal Depression | Psychiatry | Oct 2025 |
| NCT06062550 | Esketamine | Phase 4 | Scoliosis Correction | Genitourinary | Oct 2025 |
| NCT05403138 | Daratumumab | Phase 2 | Neuromyelitis Optica | Neurology | Nov 2025 |
| NCT06853431 | Esketamine | Phase 4 | Preoperative Anxiety | Psychiatry | Nov 2025 |
| NCT06087510 | Esketamine | Phase 4 | Scoliosis Correction | Genitourinary | Dec 2025 |
| NCT07001709 | Abiraterone acetate | Phase 4 | Prostate Cancer | Oncology | Dec 2025 |
| NCT04221503 | Niraparib | Phase 2 | Glioblastoma | Oncology | Jan 2026 |
| NCT06139406 | JNJ-80948543 | Phase 1 | Lymphoma, Non-Hodgkin | Oncology | Jan 2026 |
| NCT06139406 | JNJ-75348780 | Phase 1 | Lymphoma, Non-Hodgkin | Oncology | Jan 2026 |
| NCT06139406 | JNJ-87801493 | Phase 1 | Lymphoma, Non-Hodgkin | Oncology | Jan 2026 |
| NCT03941132 | Ustekinumab | Phase 2 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Feb 2026 |
| NCT06751849 | PD-1 Inhibitor | Phase 2 | Advanced NSCLC | Oncology | Mar 2026 |
| NCT06751901 | PD-1 Inhibitor | Phase 2 | Advanced NSCLC | Oncology | Mar 2026 |
| NCT05450432 | Esketamine | Phase 4 | Major Depressive Disorder | Psychiatry | Jun 2026 |
| NCT03500445 | Daratumumab | Phase 2 | Myeloma | Oncology | Jun 2026 |
| NCT06251076 | Teclistamab | Phase 4 | Multiple Myeloma | Oncology | Jun 2026 |
| NCT07317206 | Esketamine | Phase 2 | Posttraumatic Stress Disorder (PTSD) | Psychiatry | Jun 2026 |
| NCT07556172 | Esketamine | Phase 4 | Sepsis | Infectious disease | Jun 2026 |
| NCT03836014 | Daratumumab | Phase 3 | Multiple Myeloma in Relapse | Oncology | Jul 2026 |
| NCT07063199 | Daratumumab | Phase 2 | Immune Thrombocytopenia | Hematology | Aug 2026 |
| NCT06838962 | Daratumumab | Phase 2 | Immune Thrombocytopenia | Hematology | Aug 2026 |
| NCT03589222 | Daratumumab | Phase 2 | Refractory Multiple Myeloma | Oncology | Aug 2026 |
| NCT07021677 | Daratumumab | Phase 2 | T Acute Lymphoblastic Leukemia | Oncology | Aug 2026 |
| NCT06618001 | JNJ-89853413 | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Sep 2026 |
| NCT06083922 | Daratumumab | Phase 2 | Multiple Myeloma | Oncology | Oct 2026 |
| NCT05702034 | Milvexian | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | Neurology | Oct 2026 |
| NCT03479268 | Ibrutinib | Phase 1 | B-Cell Prolymphocytic Leukemia | Oncology | Nov 2026 |
| NCT05250973 | Daratumumab | Phase 2 | Amyloidosis | Metabolic and endocrine | Nov 2026 |
| NCT05117931 | Amivantamab | Phase 2 | Esophagogastric Cancer | Oncology | Nov 2026 |
| NCT03767075 | Amivantamab | Phase 2 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT06505369 | Teclistamab | Phase 2 | Multiple Myeloma | Oncology | Nov 2026 |
| NCT05526989 | Niraparib | Phase 2 | Penile Carcinoma | Oncology | Nov 2026 |
| NCT06505369 | Talquetamab | Phase 2 | Multiple Myeloma | Oncology | Nov 2026 |
| NCT05694312 | Ibrutinib | Phase 2 | Autoimmune Hemolytic Anemia | Oncology | Nov 2026 |
| NCT06859892 | Esketamine | Phase 4 | Adults | Cardiovascular | Nov 2026 |
| NCT07230860 | JNJ-95597528 | Phase 2 | Dermatitis, Atopic | Immunology | Nov 2026 |
| NCT07179913 | Esketamine | Phase 4 | Depressed | Psychiatry | Nov 2026 |
| NCT05463224 | Lazertinib | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT03767244 | Apalutamide | Phase 3 | Prostatic Neoplasms | Oncology | Dec 2026 |
| NCT04963153 | Erdafitinib (TAR-210) | Phase 1 | Locally Advanced Bladder Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05888870 | Daratumumab | Phase 4 | Hemophilia A With Inhibitor | Hematology | Dec 2026 |
| NCT06758375 | Teclistamab | Phase 2 | Multiple Myeloma, Newly Diagnosed | Oncology | Dec 2026 |
| NCT04992013 | Niraparib | Phase 2 | Metastatic Cancer | Oncology | Dec 2026 |
The 60 nearest readouts of 569 trials; the rest in the app.
Cash and short-term investments of $17.2bn on 2026-09-27; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.